15-Year watch begins for patients who got experimental cancer cell therapy
NCT ID NCT06906380
Summary
This study will monitor the long-term safety of an experimental cell therapy called ARD103 for 15 years. It will track 49 patients who previously received the therapy for relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndrome. The goal is to understand any delayed side effects and see how long the treatment's benefits last.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novant Health Cancer Institute
Charlotte, North Carolina, 28204, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novant Health Cancer Institute
Winston-Salem, North Carolina, 27201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.